Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Gilead Sciences has announced a failed second attempt to craft a one-pill, once-daily regimen containing its anti-HIV drug Truvada with Bristol-Myers Squibb's Sustiva. An initial attempt to craft the one-pill therapy failed in April. Gilead and Roche plan to consider new ways to combine the drugs, including a layering approach. They hope to file for Food and Drug Administration approval of the single-pill treatment in the first half of 2006. __________ Abbott Laboratories has announced that it is working on a new tablet formulation of protease inhibitor Kaletra. The tablet formulation would reduce the pill burden from three to two pills per day and would not have to be refrigerated. __________ Roche and Trimeris have filed for FDA approval to use the Biojector 2000 device to administer the fusion inhibitor Fuzeon. The device uses a carbon dioxide-powered injector to spray liquid medication through the skin, which could reduce injection-site reactions. A decision by the FDA is expected by the end of the year. __________ Switching to Reyataz from other protease inhibitors maintains viral suppression and results in fewer viral rebounds, improved gastrointestinal tolerance, and significant lipid improvements, according to a study presented at the Third International AIDS Society Conference on HIV Pathogenesis and Treatment. __________ Replacing Zerit with Viread can maintain virologic control while decreasing cardiovascular risks by lowering total cholesterol, 'bad' cholesterol, and triglyceride levels, according to a study discussed at the Third International AIDS Society Conference on HIV Pathogenesis and Treatment. __________ A four-nucleoside regimen containing Viread and Trizivir following treatment failure with protease inhibitor- or nonnuke-based regimens is effective in reducing blood-based viral counts to below 400 copies in 87% of adults and to below 50 copies in 59% of adults, according to a study presented at the Third International AIDS Society Conference on HIV Pathogenesis and Treatment. __________ A study discussed at the Third International AIDS Society Conference on HIV Pathogenesis and Treatment has shown that Viread does affect kidney function but rarely causes overt renal failure. __________ The FDA has given fast-track approval designation to the experimental protease inhibitor GSK-640385, being developed by GlaxoSmithKline, based on data from a Phase IIa clinical trial showing the drug was effective against strains of HIV resistant to other protease inhibitors. __________ GlaxoSmithKline launched a final Phase III clinical trial of experimental fusion inhibitor aplaviroc, formerly known as GSK-873140. The drug works by binding CCR5 receptors on the surface of immune system cells, preventing HIV from latching on to them. __________ A six-month Phase II clinical trial of the Incyte experimental nucleoside reverse transcriptase inhibitor Reverset showed the drug reduced HIV viral loads by more than 90% in more than half of all study subjects who had built up resistance to other anti-HIV medications. __________ Phase II trial data for the Tibotec experimental protease inhibitor TMC 114 shows that a Norvir-boosted dose of the medication is effective as the cornerstone of salvage therapy for triple-class-experienced HIV patients, including those resistant to other protease inhibitors. __________ Officials from 26 drug companies and 11 Latin American countries reached a deal in August to slash prices of anti-HIV medications by as much as 66%. The price cuts will remain effective for two years.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Don’t miss our latest news! Sign up today for our free newsletter.
Plus: Featured Video
Latest Stories
‘Kokomo City’ Gives a Searing Look Into Lives of Black Trans Sex Workers
August 18 2023 12:40 PM